Exchange: NYSE·Updated 03:49 PM EDT
News
all
press releases
Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare
Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.
Zacks
More News
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
Zacks
How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026
CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.
Zacks
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Zacks
Alebund Pharmaceuticals Announces 2026 Interim Results
Alebund Pharmaceuticals Announces 2026 Interim Results Alebund Pharmaceuticals Announces 2026 Interim Results PR Newswire SHANGHAI, Aug. 26, 2026 SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused...
PR Newswire
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease PR Newswire DENVER, Aug. 25, 2026 More than 10,000 members will get added...
PR Newswire
Berkshire Adds Google, Delta, Trims BofA, Kroger As Abel Taps Into Record Cash Hoard
Berkshire Adds Google, Delta, Trims BofA, Kroger As Abel Taps Into Record Cash Hoard While nowhere near as tumultuous as the transformational first quarter in Berkshire's post-Warren Buffett era which saw over a dozen names rotated in and out, in the second quarter there were a few...
Zero Hedge
Is DaVita (DVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
Zacks
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
Zacks

Advertisement|Remove ads.